Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply” and “GSK insider trading Form 4 transactions.”
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK plc has filed a Form 6-K to report its share capital and voting rights position as of 30 June 2025 under the UK Disclosure Guidance and Transparency Rule 5.6.1R. The company’s issued share capital totals 4,315,370,199 Ordinary Shares of 31 ¼ pence each, of which 226,172,571 shares are held in treasury and therefore do not carry voting rights. After adjusting for these treasury shares, the total number of voting rights currently exercisable amounts to 4,089,197,628. Shareholders should use this denominator when determining whether their holdings cross FCA disclosure thresholds. The notice is signed by Company Secretary Victoria Whyte on 1 July 2025 and provides an email address (company.secretary@gsk.com) for notifications.
On 30 June 2025, GSK plc (GSK) repurchased 483,834 ordinary shares (nominal value 31¼ p) through its broker Merrill Lynch International under the non-discretionary buyback agreement announced on 4 June 2025.
• Price range: 1,385.50p – 1,405.00p
• Volume-weighted average price: 1,397.42p
• Cash outlay: ≈ £6.8 million
Since the start of the programme (4 June 2025) the company has reacquired 8,038,188 shares. Following the latest trade GSK holds 226,172,571 shares in treasury, leaving 4,089,197,628 shares outstanding (treasury stock equals 5.53 % of voting rights).
The transaction reduces the free float by roughly 0.012 %; while financially immaterial, it signals continuing capital-return discipline and fulfils UK Disclosure Guidance & Transparency Rule obligations. Detailed venue- and trade-level data accompany the filing for regulatory transparency.
GSK plc filed a Form 6-K reporting routine activity under its June 2025 share buy-back mandate. Acting through its broker Merrill Lynch International, the company repurchased 482,114 ordinary shares (nominal value 31 ¼ p) on 27 June 2025.
Key trade metrics reported for the London Stock Exchange (XLON):
- Price range: 1,395.50 p – 1,410.50 p
- Volume-weighted average price (VWAP): 1,402.45 p
The shares will be held in treasury. Since launching the non-discretionary agreement with the broker on 4 June 2025, GSK has bought back a cumulative 7,554,354 shares.
Post-transaction, GSK’s capital structure is as follows:
- Treasury shares: 225,688,737
- Shares outstanding (excluding treasury): 4,089,681,462
- Total voting rights in issue: 4,089,681,462
- Treasury shares as a percentage of voting rights: 5.52 %
The filing also provides a full schedule of individual XLON trades and confirms no purchases occurred on CBOE venues (CHIX or BATE) on the reporting date.
GSK has reported a significant share buyback transaction on June 26, 2025. The company purchased 485,032 ordinary shares through Merrill Lynch International at prices ranging from 1,390.00p to 1,405.00p per share, with a volume-weighted average price of 1,397.83p.
Key transaction details:
- All purchases were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 225,206,623 shares in treasury
- Total voting rights now stand at 4,090,138,849
- Treasury shares represent 5.51% of voting rights
This purchase is part of GSK's ongoing buyback programme announced on June 4, 2025, under which the company has acquired 7,072,240 ordinary shares to date. The transaction demonstrates GSK's continued commitment to returning value to shareholders through its share repurchase strategy.
GSK has reported a significant share buyback transaction on June 25, 2025. The company purchased 483,629 ordinary shares at prices ranging from 1,395.00p to 1,411.00p per share, with a volume-weighted average price of 1,400.74p.
Key transaction details:
- All trades were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 224,721,591 shares in treasury
- Total voting rights now stand at 4,090,623,881
- Treasury shares represent 5.49% of voting rights
This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 6,587,208 ordinary shares, demonstrating significant progress in their capital return strategy.
GSK plc reports a significant share buyback transaction on June 24, 2025. The company purchased 476,537 ordinary shares at prices ranging from 1,403.50p to 1,421.50p per share, with a volume-weighted average price of 1,411.62p.
Key transaction details:
- All trades executed on London Stock Exchange (XLON)
- Part of existing buyback program announced June 4, 2025
- Total shares purchased since program inception: 6,103,579
- Post-transaction treasury holdings: 224,237,962 shares
- Total voting rights: 4,091,107,510
- Treasury shares represent 5.48% of voting rights
The transaction demonstrates GSK's ongoing commitment to returning value to shareholders through its share repurchase program.
GSK has reported multiple share transactions by Sally Jackson, SVP of Global Communications & CEO Office, and her associated person Dylan Jackson on June 19, 2025. The transactions include:
- Sally Jackson gifted 1,400 ordinary shares to a family member at nil consideration
- Sally Jackson sold 1,395 shares at £14.3524 and purchased 1,387 shares at £14.3378 as part of an ISA transfer
- Dylan Jackson (PCA) sold 1,395 shares at £14.3524 and purchased 1,385 shares at £14.3537 as part of an ISA transfer
All transactions were conducted on the London Stock Exchange. These share movements represent portfolio restructuring into Individual Savings Accounts (ISAs) rather than significant changes in ownership positions. The transactions were reported in compliance with regulatory requirements for PDMRs (Persons Discharging Managerial Responsibilities) and their closely associated persons.
GSK announced a significant board-level change at one of its Non-Executive Directors' external commitments. Wendy Becker, who serves as GSK's Non-Executive Director and Chair of the Remuneration Committee, has been appointed as Chair of the Board of Sony Group Corporation, effective June 24, 2025. This represents a promotion from her previous position as Vice Chair of Sony's Board.
This disclosure, filed as a Form 6-K (foreign issuer report), reflects GSK's commitment to transparency regarding its directors' external appointments and potential commitments. The appointment was officially documented by Victoria Whyte, GSK's Company Secretary.
- Filing Date: June 28, 2025
- Effective Date of Appointment: June 24, 2025
- Key Personnel: Wendy Becker (Non-Executive Director)
- New Role: Chair of Sony Group Corporation Board
- Previous Role at Sony: Vice Chair of the Board
GSK has reported a significant share buyback transaction on June 23, 2025. The company purchased 483,823 ordinary shares through Merrill Lynch International at prices ranging from 1,398.00p to 1,414.50p per share, with a volume-weighted average price of 1,403.43p.
Key transaction details:
- All trades were executed on the London Stock Exchange (XLON)
- Following this purchase, GSK holds 223,761,425 shares in treasury
- Total voting rights now stand at 4,091,584,047
- Treasury shares represent 5.47% of voting rights
This purchase is part of GSK's existing buyback program announced on June 4, 2025. Since the program's inception, the company has purchased 5,627,042 ordinary shares, demonstrating significant progress in their capital return strategy.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
What is the core business of GSK PLC?
Which therapeutic areas does GSK specialize in?
How does GSK generate revenue?
What role do joint ventures play in GSK's business model?
How is GSK positioned within the competitive pharmaceutical landscape?
What distinguishes GSK's research and development efforts?
In which geographical markets does GSK operate?
What key strengths contribute to GSK's success?
